



LiMM Therapeutics incorporated to translate breakthrough science into first in class therapeutic agents

Paris and Lisboa, June 24th 2019

LiMM Therapeutics was created to lead development of a new class of therapeutic agents - neuronal reprogrammers of innate lymphocytes. The company is based on pioneering discoveries of its Scientific Founder Henrique Veiga-Fernandes – Paul Allen Distinguished Investigator 2018 – on the cross-talk between innate immune cells and neuronal cells in the peripheral tissues.

LiMM Therapeutics is backed by leading Venture Capital Fund manager Seventure from France (investing inter alia via its fund Health For Life Capital™) and 200M Fund managed by PME investimentos in Portugal.

David Braga Malta, Founding CEO of the company emphasizes that “At LiMM we are focused on pushing forward a pipeline of first in class therapeutic agents to treat unmet medical needs in GI, Renal or Metabolic areas. Our technologies are targeting completely new and independent mechanisms of action with the potential to overcome the main problems we face when trying to treat immune mediated diseases.”

Isabelle De Cremoux, CEO of Seventure Partners, shared “Seventure was very happy to support LiMM from its foundation onwards. The company is uniquely positioned at the intersection of immune and neuronal sensing, an area that will unlock significant therapeutic potential and with clear interplay with the microbiome.”

Marco Fernandes, CEO of PMEi, stressed that “it is the first time that a biotech technology developed at a Portuguese university is able to attract such specialized and international venture capital. 200M Fund is honored to support the entrepreneurs Henrique and David and join in the syndicate to support the development of LiMM.”

LiMM Therapeutics also announced the appointment of industry leader Jacques Mizrahi as chairman on the board to support the strategic development of the company.

About LiMM Therapeutics

LiMM is a biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes - to preserve health and treat inflammatory, infectious and metabolic diseases. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.

About Seventure Partners

With €750m net commitments under management as of the end of 2018, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure has been investing in innovative businesses with high growth potential in two fields: Life sciences across Europe, Israel, Asia and North America, and Digital technologies in France and Germany

In life sciences, the main areas of focus include “classic” approaches such as biotechnology and pharmaceuticals, diagnostic and medtech, industrial biotechnology, as well as “beyond the pill” approaches such as MICROBIOME-linked innovations, nutrition, foodtech, digital/connected health and personalized medicine.

Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. In March 2018, Seventure launched AVF, a new fund dedicated to animal nutrition, feed and health with Adisseo as strategic partner.

Seventure successfully launched Health for Life Capital™ which invests in Lifesciences (health, nutrition, digital/connected health...) with a core focus on the microbiome revolution and its applications in human health, nutrition and food. The €160m first fund launched in 2014 has invested in 20 companies at the forefront of their fields, such as Enterome, Vedanta Biosciences, MaaT Pharma, Eligo Bioscience, Biomx, Daytwo, Zipongo, Microbiotica, A-mansia Biotech, Cambrooke, Mdoloris Medical Systems, LNC, Targedys, MycoTechnology, LiMM Therapeutics etc

In January 2019 it launched second fund Health for Life Capital II™ with a target fund size of over €200m.

About 200M Fund

The 200M Co-investment Fund, managed by PME Investimentos, has the purpose to foster investment in Portuguese companies in the start-up/scale-up phase (from Seed, Late Seed to Series A and B), as well as promoting the activity of Venture Capital in Portugal through the mobilization of specialized national and international Venture Capital entities that, in addition to the financial resources provided, enable companies to acquire technical, commercial and financial knowledge. The 200M Co-investment Fund is co-financed by the European Union through the European Regional Development Fund, via Fundo de Capital & Quase Capital and the Regional Operational Programs.

--

David Braga Malta (MSc, PhD)

Founder & CEO

LiMM Therapeutics

cell: +351 91 910 2726

cell: +33 (0)6 18 11 47 65

skype: davidbmalta